Last Updated : December 17, 2024
Details
FilesGeneric Name:
leuprolide mesylate
Project Status:
Active
Therapeutic Area:
Prostate cancer
Manufacturer:
Accord Healthcare Inc.
Call for patient/clinician input open:
Brand Name:
Camcevi
Project Line:
Reimbursement Review
Project Number:
PC0370-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Camcevi (leuprolide mesylate) is indicated for the treatment of adult patients with advanced prostate cancer.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
Camcevi (leuprolide mesylate) is indicated for the treatment of adult patients with advanced prostate cancer.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | October 11, 2024 |
|---|---|
| Call for patient/clinician input closed | December 06, 2024 |
| Submission received | November 22, 2024 |
| Submission accepted | - |
| Draft CADTH review report(s) provided to sponsor for comment | March 03, 2025 |
| Deadline for sponsors comments | March 12, 2025 |
| CADTH review report(s) and responses to comments provided to sponsor | May 02, 2025 |
| Expert committee meeting (initial) | May 14, 2025 |
| Draft recommendation issued to sponsor | May 27, 2025 To May 29, 2025 |
| Draft recommendation posted for stakeholder feedback | June 05, 2025 |
| End of feedback period | June 19, 2025 |
Files
Last Updated : December 17, 2024